NovoCure Limited Ordinary Shares NVCR
$17.04
-1.22%
at last close
Market Cap$2.00 billion
P/E Ratio—
Div Yield—
Volume1.34M
52-Week Range
$9.82$20.06
Key Stats
- Today's Range
- $16.86 – $17.64
- 50-Day Range
- $10.13 – $18.92
- 52-Week Range
- $9.82 – $20.06
- Volume
- 1.34 million shs
- Average Volume
- 1.73 million shs
- Market Cap
- $2.00 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 5.87
- Price / Sales
- 3.05
Short Interest
- Short Interest
- 3.03%
- Days to Cover
- 6.11
Financials (TTM)
- Revenue
- $655.35 million
- Net Income
- $-136,227,000
- Net Margin
- -20.79%
- Return on Equity
- -40.01%
- Debt-to-Equity
- —
About NovoCure Limited Ordinary Shares
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.